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The heart and great vessels were once thought to be
relatively resistant to the damaging effects of radiation
therapy (1,2). But there is now clear evidence that thoracic
irradiation may cause acute inflammation and progressive
fibrosis of the pericardial, myocardial, and endocardial
(valvular and arterial) tissues (3– 6). As new therapies
have improved survival, many patients with cancer are
now at risk for the cardiovascular complications of
radiation therapy administered years or even decades
earlier (7).
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Most clinical information about the cardiac effects of
thoracic radiation is based on studies of patients with breast
cancer or Hodgkin’s disease who developed symptomatic
disease during the course of treatment or during follow-up.
Pericardial disease is one of the most common manifesta-
tions of radiation-induced cardiac injury. Acute pericarditis
may occur early in the course of treatment, but constrictive
or effusive pericarditis may also develop months to years
after therapy (5,6,8). Other late complications include
myocardial fibrosis and cardiomyopathy, accelerated coro-
nary artery disease, conduction abnormalities, and valvular
dysfunction (8–11).
The overall incidence of clinically detectable heart injury
after thoracic irradiation is approximately 30%, although
patients treated with mantle radiation for Hodgkin’s disease
are at highest risk for developing cardiac complications
because of the proximity of the radiation field to cardiac
structures (6). In one large study of 2,232 survivors of
Hodgkin’s disease (mean age 29 years at treatment) the risk
of death from heart disease after a mean follow-up of 9.5
years was 3.9% (12). Of the 88 cardiac deaths 55 were due
to myocardial infarction. The average age at death from
infarction was 49 years, with 22 deaths in patients45 years
of age. Significant mortality also resulted from cardiomyop-
athy, valve dysfunction, and pericardial disease. The relative
risk for cardiac death was highest for patients who received
a total radiation dose to the chest of 30 Gy and were 20
years of age at the time of their treatment. Subcarinal
blocking techniques to limit radiation exposure to the heart
did not significantly reduce the risk of myocardial infarction
but reduced the incidence of other forms of cardiac injury.
The persistently high rates of myocardial infarction despite
cardioprotective techniques likely result from continued
exposure of the proximal coronary arteries to full-dose
radiation (5).
The risk of radiation-induced cardiac injury may be
further increased by the concomitant use of anthracycline-
based chemotherapy, especially when larger cumulative
doses of doxorubicin (450 mg/m2) are used, when radia-
tion and chemotherapy are given concurrently, and when
high dose-volumes of cardiac radiation are administered
(13–15). In addition, other known cardiac risk factors such
as tobacco use, hypertension, and hyperlipidemia further
increase the risk of coronary atherosclerosis, myocardial
infarction, and sudden death (16,17).
Despite the insights gathered from previous studies, little
is known about the prevalence of preclinical heart disease
following thoracic radiation, and whether asymptomatic
patients would benefit from systematic screening. In this
issue of the Journal, Heidenriech et al. (18) address this
problem by using electrocardiography and echocardiography
to examine 254 patients with no symptoms or physical signs
of heart disease who had received at least 35 Gy of mantle
radiation as treatment for Hodgkin’s disease. Time from
irradiation to examination ranged from 2 to 33 years (mean
15 years). When these patients were compared with age-
matched controls, patients treated with thoracic radiation
had a much higher prevalence of valve disease, especially
aortic regurgitation, and the severity of disease increased
with time following therapy. Sixty percent of patients
more than 20 years post-irradiation had at least mild
aortic regurgitation, whereas 15% had moderate or severe
aortic regurgitation. Despite the high prevalence of aortic
valve disease in these patients, aortic regurgitation was
rarely diagnosed by physical examination. Thus, echocar-
diography was clearly a useful screening tool to detect
valve disease for which endocarditis prophylaxis should
be recommended. In addition to valve disease, pericardial
thickening, regional hypokinesis, mildly depressed left
ventricular systolic function, and lower left ventricular
mass were far more often observed in the radiation-
treated patients.
How does this new information help the clinician eval-
uate the asymptomatic patient who has received thoracic
radiation? This study clearly shows that a significant per-
centage of patients with Hodgkin’s disease who were treated
with mediastinal radiation developed significant valvular
disease or mild left ventricular dysfunction, two abnormal-
ities that are easily detected by echocardiography and may
benefit from therapy (19). Importantly, the prevalence and
severity of these abnormalities increased considerably over
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time, making a strong argument for screening because they
remained clinically unrecognized. On the other hand, as the
authors note, radiation therapy has been modified in the
past 30 years to reduce the total radiation dose administered
and to better shield the cardiac structures. The prevalence of
these cardiac abnormalities will thus likely decrease in
patients treated more recently. More patients will have to be
screened in the future to identify those that might poten-
tially benefit from intervention.
In addition, although resting echocardiography is an
excellent tool for evaluating valve or ventricular dysfunction,
it is less useful for diagnosing coronary artery disease or
pericardial thickening. More sensitive techniques, such as
computerized tomography or magnetic resonance imaging,
may prove much more effective in detecting such patholo-
gies. Prognostic assessment of coronary arterial disease with
exercise echocardiography to reduce the substantial cardio-
vascular mortality among these young patients also deserves
investigation.
These data may not be applicable to patients who
received thoracic radiation for other types of malignancies in
which the degree of cardiac exposure and the use of
concomitant chemotherapy differ significantly from the
present study. However, the high prevalence of cardiac
disease argues for close observation of patients with
Hodgkin’s disease who have received mediastinal radiation.
A yearly history and physical examination with close atten-
tion to symptoms and signs of heart disease that might
otherwise be overlooked in this generally young population
is essential. In patients who remain asymptomatic, screening
echocardiography 10 years after treatment appears reason-
able given the high likelihood of diagnosing significant
cardiac pathology. The study by Heidenreich et al. (18) does
not address whether treatment of asymptomatic disease will
prevent progression of disease or future cardiac events; but
these patients may derive benefit from therapies such as
antibiotic prophylaxis for significant valve disease and an-
giotensin II-converting enzyme inhibitors for the treatment
of left ventricular dysfunction. Aggressive treatment of
cardiac risk factors, especially hyperlipidemia, both at the
time of cardiac therapy and during follow-up, may reduce
the degree of initial cardiac injury and slow the progression
of vascular, myocardial, and valvular fibrosis (19). Finally,
newer treatment strategies that use lower total radiation
doses, minimize cardiac exposure by subcarinal shielding
techniques, and avoid concurrent cardiotoxic chemothera-
peutic agents may help reduce the incidence of serious
cardiac disease in the future.
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